Moleculin Biotech (MBRX) Tops Q2 EPS by 7c

Moleculin Biotech (NASDAQ: MBRX) reported Q2 EPS of ($0.20), $0.07 better than the analyst estimate of ($0.27).

For earnings history and earnings-related data on Moleculin Biotech (MBRX) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Energy Fuels to acquire rare earth magnet maker VAC for $1.9 billion
• Prosperity Bancshares (PB) Reiterated at Overweight by Cantor Fitzgerald as Estimates Revised